The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies

@article{Shain2014TheBR,
  title={The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies},
  author={Kenneth Shain and Jianguo Tao},
  journal={Oncogene},
  year={2014},
  volume={33},
  pages={4107-4113}
}
Specific niches within the lymphoma tumor microenvironment (TME) provide sanctuary for subpopulations of tumor cells through stromal cell–tumor cell interactions. These interactions notably dictate growth, response to therapy and resistance of residual malignant B cells to therapeutic agents. This minimal residual disease (MRD) remains a major challenge in the treatment of B-cell malignancies and contributes to subsequent disease relapse. B-cell receptor (BCR) signaling has emerged as essential… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 82 references

In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients

  • SEM Herman, M Farooqui, R Bezabhie, G Aue, A. Wiestner
  • ASH Annual Meeting Abstracts
  • 2012

In vivo inhibition of BCR activation in high-risk CLL patients on therapy with Bruton’s tyrosine kinase inhibitor ibrutinib: correlative studies from an ongoing phase 2 clinical trial

  • J Hoellenriegel, S O0Brien, MJ Keating, WG Wierda, JJ Buggy, JA. Burger
  • ASH Annual Meeting Abstracts
  • 2012

Similar Papers

Loading similar papers…